Security key
74065P101
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)
CUSIP: 74065P101
Q1 2022 13F Holders as of 31 Mar 2022
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 34,109,145
- Total 13F value
- $235,382,986
- Share change
- -1,039,320
- SEC-reported price per share
- $6.90
- Number of holders
- 64
- Value change
- -$10,995,652
- Number of buys
- 28
- Number of sells
- 43
- Shares outstanding
- 64,968,808
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2022
Institutions
64
Top holders
10
PRLD full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Prelude Therapeutics Inc SEC filings
Prelude Therapeutics Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74065P101
Recent filing periods:
Ownership snapshot
Top reported holders of PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BAKER BROS. ADVISORS LP
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
15/15
Latest evidence
31 Dec 2021
13F
Lead comparable stake: 16%
Showing 1-6 of 15 holder rows.
Quick read
BAKER BROS. ADVISORS LP leads the comparable SEC ownership view at 16%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BAKER BROS. ADVISORS LP's linked filing trail.
Comparable ownership
Top 5
BAKER BROS. ADVISORS LP
16%
ORBIMED ADVISORS LLC
15%
FMR LLC
9.1%
UBS AM, a distinct business unit ...
2.3%
BlackRock Finance, Inc.
1.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP |
13F
Company
|
16%
|
$126,042,000
10,123,824 shares
|
— | 31 Dec 2021 |
| ORBIMED ADVISORS LLC |
13F
Company
|
15%
|
$124,994,000
10,039,691 shares
|
— | 31 Dec 2021 |
| FMR LLC |
13F
Company
|
9.1%
|
$73,939,000
5,938,933 shares
|
— | 31 Dec 2021 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
Company
|
2.3%
|
$18,845,391
1,513,686 shares
|
— | 31 Dec 2021 |
| BlackRock Finance, Inc. |
13F
Company
|
1.4%
|
$11,161,000
896,504 shares
|
— | 31 Dec 2021 |
| MORGAN STANLEY |
13F
Company
|
1.3%
|
$10,528,000
845,697 shares
|
— | 31 Dec 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
64
Shares
34,109,145
Rows available
64
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2022 vs Q3 2025 Across Filers
Q3 2025 holders
45
Q1 2022 holders
64
Holder diff
19
| Investor | Q3 2025 Shares | Q1 2022 Shares | Share Diff | Share Chg % | Q3 2025 value | Q1 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend